Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All...
  • Videos
  • Collections
    • Recently published
    • Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • About
  • Editors
  • Consulting Editors
  • For authors
  • Transfers
  • Current issue
  • Past issues
  • By specialty
  • Contact
  • Recently published
  • Technical Advances
  • Clinical Medicine
  • Editorials
  • Top read articles
Comparative pathogenesis of Ebola virus and Reston virus infection in humanized mice
Beatriz Escudero-Pérez, … , Estefanía Rodríguez, César Muñoz-Fontela
Beatriz Escudero-Pérez, … , Estefanía Rodríguez, César Muñoz-Fontela
Published November 1, 2019; First published September 24, 2019
Citation Information: JCI Insight. 2019;4(21):e126070. https://doi.org/10.1172/jci.insight.126070.
View: Text | PDF
Categories: Research Article Infectious disease Virology

Comparative pathogenesis of Ebola virus and Reston virus infection in humanized mice

  • Text
  • PDF
Abstract

Filoviruses of the genus Ebolavirus include 6 species with marked differences in their ability to cause disease in humans. From the highly virulent Ebola virus to the seemingly nonpathogenic Reston virus, case fatality rates can range between 0% and 90%. In order to understand the molecular basis of these differences, it is imperative to establish disease models that recapitulate human disease as faithfully as possible. Nonhuman primates (NHPs) are the gold-standard models for filovirus pathogenesis, but comparative studies are skewed by the fact that Reston virus infection can be lethal for NHPs. Here we used HLA-A2–transgenic, NOD–scid–IL-2γ receptor–knockout (NSG-A2) mice reconstituted with human hematopoiesis to compare Ebola virus and Reston virus pathogenesis in a human-like environment. While markedly less pathogenic than Ebola virus, Reston virus killed 20% of infected mice, a finding that was linked to exacerbated inflammation and viral replication in the liver. In addition, the case fatality ratios of different Ebolavirus species in humans were recapitulated in the humanized mice. Our findings point to humanized mice as a putative model to test the pathogenicity of newly discovered filoviruses, and suggest that further investigations on Reston virus pathogenesis in humans are warranted.

Authors

Beatriz Escudero-Pérez, Paula Ruibal, Monika Rottstegge, Anja Lüdtke, Julia R. Port, Kristin Hartmann, Sergio Gómez-Medina, Jürgen Müller-Guhl, Emily V. Nelson, Susanne Krasemann, Estefanía Rodríguez, César Muñoz-Fontela

×

Figure 1

Mucosal exposure of huNSG-A2 mice to EBOV and RESTV.

Options: View larger image (or click on image) Download as PowerPoint
Mucosal exposure of huNSG-A2 mice to EBOV and RESTV.
(A) Flow cytometry–...
(A) Flow cytometry–based evaluation of the presence of mature human immune cells in skin (lower back area) and lung of huNSG-A2 mice. Gates indicate the percentage of cells expressing human CD45 (h-CD45) in either organ. The gating strategy in the right panels shows the presence of human antigen-presenting cells (APCs) (G1), B cells (G2), CD14+ monocytes (G3), CD16+ monocytes (G4), nonmonocytic APCs (G5), and human DC subsets (G6–G8). (B) Histopathological analysis of huNSG-A2 lung tissue after infection with EBOV or RESTV on the indicated days after infection. White arrowheads indicate the presence of infected cells, showing EBOV NP– and CD45-positive staining. Scale bar: 50 μm (C) Histopathology score (ordinal method, values of 0 to 5) assessing the levels of hCD45 staining in n = 3 lung sections of RESTV- and EBOV-infected and control (Mock) mice. Box-and-whisker plots represent minimum to maximum values. All scoring values are shown.
Follow JCI Insight:
Copyright © 2019 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts